Skip to content
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Nephrology

Prognosis and the Long-Term Outlook

At a Glance

Fanconi renotubular syndrome 3 has no single predictable course: some people have no symptoms or mild urine changes, while others develop bone disease, electrolyte problems, or reduced kidney function. Lifelong monitoring is important because the EHHADH variant alone cannot predict severity.

Because Fanconi renotubular syndrome 3 (FRTS3) is exceptionally rare, with only a small number of families documented in the world, our understanding of its long-term prognosis is limited [1][2]. What the medical literature makes clear, however, is that there is no single, predictable outcome. Instead, FRTS3 is a condition of extreme variability [1].

The Spectrum of Health

When doctors look at the small number of people diagnosed with FRTS3, they see a wide range of experiences—even among family members who share the exact same EHHADH variant [1][2].

  • People with the Variant Who Are Currently Asymptomatic: Some people have the pathogenic variant but have minimal or no physical symptoms. In one reported case, a 54-year-old father was discovered to have the variant only after his child became ill; the father appeared otherwise healthy [2]. It is important to note that absence of symptoms does not establish a zero risk of later laboratory abnormalities.
  • Mild or Isolated Findings: Other individuals may only have “silent” lab abnormalities, such as glucosuria (sugar in the urine) or mild proteinuria (protein in the urine), but they do not develop immediate bone disease or kidney failure [1].
  • Generalized Fanconi Syndrome: On the other end of the spectrum, some patients develop the full syndrome, including bone softening (rickets or osteomalacia) and significant electrolyte imbalances that require multiple daily supplements [1][2].

Long-Term Kidney Function

One of the most important questions for patients is whether the condition will lead to chronic kidney disease (CKD) or kidney failure. Because the reports are small, there are no dependable percentages or predictions available. Currently, the evidence shows two different patterns:

  1. Stable Function: In the first families ever described with FRTS3, some patients maintained normal or only slightly reduced kidney function well into their later years [1][3].
  2. Early Impairment: More recent reports have identified a few individuals who experienced a decline in kidney function (impaired eGFR) at a much younger age [1].

This means that doctors cannot guarantee a “mild” course for everyone based simply on the genetic variant. This variability is why life-long monitoring is required [1][2].

Why We Can’t Predict the Future (Yet)

In many genetic diseases, knowing the specific variant allows doctors to predict how severe the disease will be. In FRTS3, this is not yet possible. The most commonly reported variant, p.E3K, has been found in people with no symptoms and in people with early kidney impairment [1][2].

Scientists hypothesize there may be other modifier genes or environmental factors that influence the severity of the disease [4][2].

Living with Uncertainty

The lack of a “typical” case can be frustrating, but the goal of long-term care is to reduce preventable complications and detect changes early by:

  • Preventing severe dehydration, which can stress the kidneys [5].
  • Carefully monitoring phosphate and vitamin D therapy to avoid nephrocalcinosis (calcium deposits in the kidney) [2][6].
  • Maintaining a normal acid-base balance to support bone and muscle health [7].

By staying closely connected to a rare-disease specialist, you ensure that any changes in your kidney health or electrolytes are managed proactively based on your individual needs [8][1].

Common questions in this guide

What is the long-term outlook for Fanconi renotubular syndrome 3?
FRTS3 does not have one predictable long-term course because only a small number of families have been studied. Some people have no symptoms or only mild urine abnormalities, while others develop generalized Fanconi syndrome, bone disease, electrolyte problems, or reduced kidney function. Lifelong monitoring is important.
Can FRTS3 lead to chronic kidney disease or kidney failure?
FRTS3 can be associated with reduced kidney function, but the available reports are too small to estimate an individual’s risk of chronic kidney disease or kidney failure. Some people have maintained normal or mildly reduced kidney function into later life, while others have experienced decline at a younger age. Regular follow-up can help identify changes early.
Does the EHHADH p.E3K variant predict how severe FRTS3 will be?
No. The p.E3K variant has been reported in people without symptoms as well as in people with early kidney impairment, so the variant alone does not reliably predict the course of FRTS3. Other genetic or environmental factors may affect severity.
What monitoring is important for someone with FRTS3?
Long-term follow-up usually focuses on kidney function, urine findings, electrolytes, acid-base balance, and the effects of phosphate or vitamin D therapy. Clinicians may also look for nephrocalcinosis and advise measures to prevent severe dehydration. A nephrologist or rare-disease specialist can tailor monitoring to the individual.
Can a healthy-looking relative still carry the FRTS3 variant?
Yes. Some people who carry the pathogenic variant have few or no physical symptoms and are identified only after a family member becomes ill. Having no symptoms does not prove that later laboratory abnormalities cannot occur, so genetic counseling can help relatives understand whether targeted testing is appropriate.
Why is nephrocalcinosis monitored in FRTS3?
Nephrocalcinosis means calcium deposits have formed in the kidneys. It can increase concern about future kidney complications, so clinicians may use imaging such as ultrasound while carefully managing phosphate and vitamin D therapy.

Get notified when new evidence is published on Fanconi renotubular syndrome 3.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    A puzzling renal Fanconi syndrome.

    Haydock L, Hureaux M, Hoffmann M, et al.

    Clinical kidney journal 2025; (18(8)):sfae408 doi:10.1093/ckj/sfae408.

    PMID: 40800210
  2. 2

    The recurrent p.Glu3Lys variant in EHHADH is responsible for Fanconi syndrome with early liver dysfunction and mitochondrial abnormalities.

    Rollier P, Cospain A, Barth M, et al.

    Molecular genetics and metabolism reports 2025; (43()):101214 doi:10.1016/j.ymgmr.2025.101214.

    PMID: 40242153
  3. 3

    Inherited Fanconi renotubular syndromes: unveiling the intricacies of hypophosphatemic rickets/osteomalacia.

    Ragate DC, Memon SS, Karlekar M, et al.

    Journal of bone and mineral metabolism 2024; (42(2)):155-165 doi:10.1007/s00774-023-01490-3.

    PMID: 38310177
  4. 4

    Renal Fanconi Syndrome Is Caused by a Mistargeting-Based Mitochondriopathy.

    Assmann N, Dettmer K, Simbuerger JMB, et al.

    Cell reports 2016; (15(7)):1423-1429 doi:10.1016/j.celrep.2016.04.037.

    PMID: 27160910
  5. 5

    Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report.

    Zilwa N, Mpejane O, Mehboob G, et al.

    Antiviral therapy 2023; (28(3)):13596535231186727 doi:10.1177/13596535231186727.

    PMID: 37368845
  6. 6

    Skeletal Consequences of Nephropathic Cystinosis.

    Florenzano P, Ferreira C, Nesterova G, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2018; (33(10)):1870-1880 doi:10.1002/jbmr.3522.

    PMID: 29905968
  7. 7

    Renal Tubular Acidosis.

    Bagga A, Sinha A

    Indian journal of pediatrics 2020; (87(9)):733-744 doi:10.1007/s12098-020-03318-8.

    PMID: 32591997
  8. 8

    Management of bone disease in cystinosis: Statement from an international conference.

    Hohenfellner K, Rauch F, Ariceta G, et al.

    Journal of inherited metabolic disease 2019; (42(5)):1019-1029 doi:10.1002/jimd.12134.

    PMID: 31177550

This page is for informational purposes only and does not constitute medical advice about FRTS3 prognosis. Discuss your kidney function, treatments, and family testing with your nephrologist or genetics team.